Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Reprogramming the Tumor Microenvironment to Improve Immunotherapy: Emerging Strategies and Combination Therapies
Meenal Datta, Lisa M. Coussens, Hiroyoshi Nishikawa, et al.
American Society of Clinical Oncology Educational Book (2019), Iss. 39, pp. 165-174
Open Access | Times Cited: 152

Showing 1-25 of 152 citing articles:

The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma
Matthias Pinter, Rakesh K. Jain, Dan G. Duda
JAMA Oncology (2020) Vol. 7, Iss. 1, pp. 113-113
Open Access | Times Cited: 254
Combining microenvironment normalization strategies to improve cancer immunotherapy
Fotios Mpekris, Chrysovalantis Voutouri, James W. Baish, et al.
Proceedings of the National Academy of Sciences (2020) Vol. 117, Iss. 7, pp. 3728-3737
Open Access | Times Cited: 227
Targeting hypoxia in the tumor microenvironment: a potential strategy to improve cancer immunotherapy
Bin Wang, Qin Zhao, Yuyu Zhang, et al.
Journal of Experimental & Clinical Cancer Research (2021) Vol. 40, Iss. 1
Open Access | Times Cited: 210
Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups
Matthias Pinter, Bernhard Scheiner, Markus Peck‐Radosavljevic
Gut (2020) Vol. 70, Iss. 1, pp. 204-214
Open Access | Times Cited: 195
Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities
Stephen P. Hack, Andrew X. Zhu, Yulei Wang
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 195
Synergistic immunotherapy of glioblastoma by dual targeting of IL-6 and CD40
Fan Yang, Zhenqiang He, Hao Duan, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 115
Clinical and translational advances in ovarian cancer therapy
Panagiotis A. Konstantinopoulos, Ursula A. Matulonis
Nature Cancer (2023) Vol. 4, Iss. 9, pp. 1239-1257
Closed Access | Times Cited: 99
Immunology and immunotherapy of cholangiocarcinoma
Tim F. Greten, Robert F. Schwabe, Nabeel Bardeesy, et al.
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 6, pp. 349-365
Closed Access | Times Cited: 81
PHGDH-mediated endothelial metabolism drives glioblastoma resistance to chimeric antigen receptor T cell immunotherapy
Duo Zhang, Albert M. Li, Guanghui Hu, et al.
Cell Metabolism (2023) Vol. 35, Iss. 3, pp. 517-534.e8
Closed Access | Times Cited: 54
Targeting PAK4 to reprogram the vascular microenvironment and improve CAR-T immunotherapy for glioblastoma
Wenjuan Ma, Yanling Wang, Rongxin Zhang, et al.
Nature Cancer (2020) Vol. 2, Iss. 1, pp. 83-97
Open Access | Times Cited: 88
Integrating tumor hypoxic stress in novel and more adaptable strategies for cancer immunotherapy
Raefa Abou Khouzam, Goutham Hassan Venkatesh, Rania F. Zaarour, et al.
Seminars in Cancer Biology (2020) Vol. 65, pp. 140-154
Open Access | Times Cited: 80
Ultrasound in tumor immunotherapy: Current status and future developments
Yi-Ju Ho, Ju-Pi Li, Ching‐Hsiang Fan, et al.
Journal of Controlled Release (2020) Vol. 323, pp. 12-23
Closed Access | Times Cited: 75
YTHDF1 and YTHDF2 are associated with better patient survival and an inflamed tumor-immune microenvironment in non–small-cell lung cancer
Kazuo Tsuchiya, Katsuhiro Yoshimura, Yusuke Inoue, et al.
OncoImmunology (2021) Vol. 10, Iss. 1
Open Access | Times Cited: 71
Vascular Microenvironment, Tumor Immunity and Immunotherapy
Zachary L Lamplugh, Yi Fan
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 69
SLIT2/ROBO signaling in tumor-associated microglia and macrophages drives glioblastoma immunosuppression and vascular dysmorphia
Luiz Henrique Geraldo, Yunling Xu, Laurent Jacob, et al.
Journal of Clinical Investigation (2021) Vol. 131, Iss. 16
Open Access | Times Cited: 68
Modulation of the tumor microenvironment (TME) by melatonin
Mu Qi, Masoud Najafi
European Journal of Pharmacology (2021) Vol. 907, pp. 174365-174365
Closed Access | Times Cited: 65
Optical Imaging in the Second Near Infrared Window for Vascular Bioimaging
Zi-An Wang, Xuan Wang, Jian‐Bo Wan, et al.
Small (2021) Vol. 17, Iss. 43
Closed Access | Times Cited: 58
PET Molecular Imaging: A Holistic Review of Current Practice and Emerging Perspectives for Diagnosis, Therapeutic Evaluation and Prognosis in Clinical Oncology
Valentin Duclos, Alex Iep, Léa Gomez, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 8, pp. 4159-4159
Open Access | Times Cited: 57
Clinical Activity and Safety of Penpulimab (Anti-PD-1) With Anlotinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: An Open-Label, Multicenter, Phase Ib/II Trial (AK105-203)
Chun Han, Sisi Ye, Chunhong Hu, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 55
Reimagining antibody-dependent cellular cytotoxicity in cancer: the potential of natural killer cell engagers
Sheena Pinto, Jens Pahl, Arndt Schottelius, et al.
Trends in Immunology (2022) Vol. 43, Iss. 11, pp. 932-946
Open Access | Times Cited: 44
Addressing CPI resistance in NSCLC: targeting TAM receptors to modulate the tumor microenvironment and future prospects
Solange Peters, Luís Paz-Ares, Roy S. Herbst, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 7, pp. e004863-e004863
Open Access | Times Cited: 40
Dihydroartemisinin inhibits the growth of pancreatic cells by inducing ferroptosis and activating antitumor immunity
Hongbo Zhang, Yuzhen Zhuo, Dihua Li, et al.
European Journal of Pharmacology (2022) Vol. 926, pp. 175028-175028
Closed Access | Times Cited: 35
Photoactivatable nanoagonists chemically programmed for pharmacokinetic tuning and in situ cancer vaccination
Jianqin Wan, Lulu Ren, Xiaoyan Li, et al.
Proceedings of the National Academy of Sciences (2023) Vol. 120, Iss. 8
Open Access | Times Cited: 33
Small-molecule toosendanin reverses macrophage-mediated immunosuppression to overcome glioblastoma resistance to immunotherapy
Fan Yang, Duo Zhang, Haowen Jiang, et al.
Science Translational Medicine (2023) Vol. 15, Iss. 683
Closed Access | Times Cited: 23
MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy
Kai He, David Berz, Shirish M. Gadgeel, et al.
Journal of Thoracic Oncology (2023) Vol. 18, Iss. 7, pp. 907-921
Open Access | Times Cited: 19
Page 1 - Next Page

Scroll to top